Gilead and Merck Report Promising Phase 3 Results for Weekly HIV Regimen Islatravir/Lenacapavir
Gilead and Merck announced topline Phase 3 results for the investigational once-weekly HIV regimen islatravir/lenacapavir (ISL/LEN) from ISLEND-1 and ISLEND-2, showing the Week 48 primary endpoint was met and non‑inferiority to Biktarvy or standard therapy with a comparable safety profile. The companies plan regulatory filings and full data presentations at a future congress, potentially introducing the first weekly oral HIV treatment if approved.